Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Clarithromycin

FDA-approved product (tablet, oral), marketed as Biaxin, Biaxin Xl, Clarithromycin.

Registered studies
50+
Lab records
25
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Clarithromycin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Chronic bronchitis
  • Duodenal ulcer
  • Infection
  • Maxillary sinusitis
  • Otitis media
  • Pharyngitis
  • Pneumonia
  • Recurrent tonsillitis
  • Sinusitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Macrolides
FDA pharmacologic class
Macrolide Antimicrobial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01FA09

Repurposing investigation

Clarithromycin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA66.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli63.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae75.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis75.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 10 of 12 lab records
  • E. coli: measured active in 2 of 4 lab records
  • K. pneumoniae: measured active in 7 of 7 lab records
  • M. tuberculosis: measured active in 1 of 2 lab records
Open Clarithromycin in ChEMBL Registered studies below
Show the 25 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Clarithromycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Clarithromycin, Amoxicillin, and Metronidazole Based Regimens to Treat Helicobacter Pylori Infections in Colombia

    NCT00719420 · start 2006-04

    Registered record
    Registry ID
    NCT00719420
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Clarithromycin, Metronidazole, Amoxicillin (+Omeprazole); Clarithromycin, Amoxicillin, Omeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-04
    Completion
    2007-02
    Enrolment
    151

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionClarithromycin, Metronidazole, Amoxicillin (+Omeprazole); Clarithromycin, Amoxicillin, Omeprazole
    PhasePhase 3
    Registry statusCompleted

  • The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy

    NCT00983034 · start 2006-03

    Registered record
    Registry ID
    NCT00983034
    Conditions
    Nephrotic Syndrome; Glomerulonephritis; Membranous Nephropathy
    Interventions
    lansoprazole, amoxicillin, clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-03
    Completion
    2009-07
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNephrotic Syndrome; Glomerulonephritis; Membranous Nephropathy
    Interventionlansoprazole, amoxicillin, clarithromycin
    PhaseNot applicable
    Registry statusCompleted

  • Intravenous Clarithromycin in Septic Syndrome

    NCT00297674 · start 2004-06

    Registered record
    Registry ID
    NCT00297674
    Conditions
    Sepsis; Ventilator Associated Pneumonia
    Interventions
    Intravenous Clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-06
    Completion
    2005-12
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis; Ventilator Associated Pneumonia
    InterventionIntravenous Clarithromycin
    PhasePhase 4
    Registry statusCompleted

  • Clarithromycin 500 mg Tablets Under Non-Fasting Conditions

    NCT00836706 · start 2002-07

    Registered record
    Registry ID
    NCT00836706
    Conditions
    Healthy
    Interventions
    clarithromycin; BIAXIN®
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2002-07
    Completion
    2002-07
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionclarithromycin; BIAXIN®
    PhasePhase 1
    Registry statusCompleted

  • Risk of Acute Liver Injury in Users of Antimicrobials

    NCT01434173 · start 2001-07

    Registered record
    Registry ID
    NCT01434173
    Conditions
    Drug-Induced Liver Injury
    Interventions
    Moxifloxacin (Avelox, BAY12-8039); Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2001-07
    Completion
    2009-03
    Enrolment
    1,299,056

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug-Induced Liver Injury
    InterventionMoxifloxacin (Avelox, BAY12-8039); Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
    PhaseNot recorded
    Registry statusCompleted